Ikena Oncology, Inc. (NASDAQ:IKNA - Get Free Report)'s share price shot up 1.5% during mid-day trading on Tuesday . The company traded as high as $1.42 and last traded at $1.37. 59,559 shares traded hands during mid-day trading, a decline of 48% from the average session volume of 115,369 shares. The stock had previously closed at $1.35.
Ikena Oncology Stock Performance
The company has a market capitalization of $66.12 million, a P/E ratio of -1.59 and a beta of 0.50. The firm's fifty day moving average is $1.26 and its 200-day moving average is $1.34.
Ikena Oncology (NASDAQ:IKNA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.03. As a group, analysts expect that Ikena Oncology, Inc. will post -0.91 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the company. BML Capital Management LLC grew its position in shares of Ikena Oncology by 3.5% during the 1st quarter. BML Capital Management LLC now owns 3,710,803 shares of the company's stock valued at $4,750,000 after acquiring an additional 124,937 shares during the period. Gilead Sciences Inc. bought a new position in shares of Ikena Oncology in the fourth quarter worth approximately $3,294,000. Geode Capital Management LLC increased its holdings in shares of Ikena Oncology by 21.0% in the 4th quarter. Geode Capital Management LLC now owns 327,962 shares of the company's stock worth $538,000 after buying an additional 56,936 shares during the last quarter. Aldebaran Capital LLC purchased a new stake in Ikena Oncology during the first quarter valued at about $317,000. Finally, JPMorgan Chase & Co. lifted its position in Ikena Oncology by 18,244.1% in the 4th quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company's stock worth $255,000 after buying an additional 154,892 shares during the last quarter. 75.00% of the stock is owned by institutional investors.
About Ikena Oncology
(
Get Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ikena Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.
While Ikena Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
